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Abstract 
 
Objective:  To determine whether the benefits of dapagliflozin in patients with heart failure 
and reduced ejection fraction (HFrEF) and type 2 diabetes in DAPA-HF varied by 
background glucose-lowering therapy (GLT).  
Research design and methods: We examined the effect of study treatment by the use or not 
of GLT, and by GLT classes and combinations.  The primary outcome was a composite of 
worsening HF (hospitalization or urgent visit requiring intravenous therapy) or 
cardiovascular death.  
Results: In the 2139 type 2 diabetes patients, the effect of dapagliflozin on the primary 
outcome was consistent by GLT use/no use (hazard ratio 0.72 [95%CI 0.58-0.88] versus 0.86 
[0.60-1.23]; P-interaction=0.39) and across GLT classes.  
Conclusions: In DAPA-HF, dapagliflozin improved outcomes irrespective of use/no use of 
GLT or by GLT type used in patients with type 2 diabetes and HFrEF. 
 
Trial Registration - ClinicalTrials.gov Identifier: NCT03036124 
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INTRODUCTION 
Although sodium glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve 
cardiovascular outcomes in patients with type 2 diabetes,  they are usually prescribed as 
second-line glucose-lowering therapy (GLT), most often in addition to metformin.
1–3
  
Uncertainty about the place of SGLT2i in the management of patients with type 2 diabetes is 
reflected in differing recommendations in recent guidelines.
4–8
 The placebo-controlled 
Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF), in 
which the SGLT2i dapagliflozin reduced the risk of worsening heart failure (HF) and 
cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF), 
provides a unique opportunity to examine the efficacy of SGLT2i alone and in combination 
with other GLT in patients with type 2 diabetes.
9
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 RESEARCH DESIGN AND METHODS 
 
DAPA-HF was a prospective, randomized, double-blind, placebo-controlled trial in patients 
with HFrEF, which evaluated the efficacy and safety of dapagliflozin 10 mg once daily, 
compared with placebo, added to standard care.
9,10
 
 
In this post-hoc analysis, we included randomized patients with either undiagnosed (defined 
as central laboratory HbA1c ≥6.5% (48mmol/mol) at both screening and randomisation 
visits) or a medical history of type 2 diabetes. We examined the effect of dapagliflozin, 
compared with placebo, in subgroups (limited to those with >200 individuals to minimize the 
likelihood of type 1 error
 
) by the use, or not of background GLT and by individual GLT 
classes (biguanides [hereafter referred to as metformin], sulfonylureas, dipeptidyl peptidase 4 
[DPP-4] inhibitors and insulin). We examined the primary outcome, a composite of an 
episode of worsening HF (either an unplanned hospitalization or an urgent visit resulting in 
intravenous therapy for HF) or cardiovascular death, along with the individual components of 
cardiovascular death and HF hospitalization, and the prespecified secondary endpoints of all-
cause mortality and the composite of total (first and recurrent) HF hospitalizations and 
cardiovascular death.  
 
The cumulative incidence of the primary endpoint by treatment group in subgroups of interest 
was plotted using the Kaplan-Meier method. The effect of dapagliflozin compared with 
placebo was examined using Cox proportional-hazards models adjusted for history of 
hospitalization for HF and treatment-group assignment. An interaction test using a subgroup-
by-randomized treatment interaction term was performed to assess for treatment effect 
modification within each subgroup. Analyses were performed using Stata version 16 (College 
Station, TX, USA). A p-value <0.05 was considered statistically significant. 
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RESULTS 
Of the 4744 randomized patients in DAPA-HF, 1983 (41.8%) had a documented medical 
history of type 2 diabetes and 156 (3.3%) had undiagnosed type 2 diabetes. Therefore, 2139 
(45.1%) patients with type 2 diabetes were included in the analysis. Of these, 1596 (74.6%) 
were treated with GLT: metformin (47.7%), insulin (25.2%), sulfonylurea (20.6%), DPP-4 
inhibitor (14.5%) and glucagon-like peptide-1 (GLP-1) receptor agonist (1.0%) (each alone 
or in combination). The baseline characteristics of patients by use of GLT and type of GLT 
are summarised in Supplemental Table 1 and 2.  
 
Supplemental Figure 1 shows the cumulative incidence of the primary composite endpoint by 
randomized treatment in the subgroups of interest. The effect of dapagliflozin on the primary 
endpoint was consistent in patients taking GLT (hazard ratio 0.72 95%CI 0.58-0.88), and in 
those who were drug-naïve (0.86, 0.60-1.23; interaction p=0.39) (Figure 1). When 
considering individual GLT classes (Figure 1) or combinations (Supplemental Figure 2) there 
was no statistically significant interaction between background GLT and the effect of 
randomized therapy on the primary composite outcome.  
 
In general, the effect of dapagliflozin on each of cardiovascular death and HF hospitalization, 
was similar for individual GLT (Supplemental Figure 3) and combinations of these 
(Supplement Figure 2). Furthermore, no modification of treatment effect by background GLT 
was observed for the composite endpoint of total (first and recurrent) HF hospitalizations and 
cardiovascular death (Supplement Figure 4) or all-cause mortality (Supplement Figure 5). 
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DISCUSSION 
 
In this post-hoc analysis of DAPA-HF we found that the benefit of dapagliflozin, compared 
with placebo, in patients with type 2 diabetes and HFrEF was not influenced by background 
GLT use. The benefit of dapagliflozin was consistent in drug-naïve patients and across all 
classes of commonly used GLT, including metformin. 
 
Perhaps the most interesting group of participants were the approximately 25% of individuals 
with type 2 diabetes in DAPA-HF who were not prescribed any GLT at baseline i.e. those in 
which randomized dapagliflozin became “first-line” GLT and pharmacological 
“monotherapy”. Despite limited power for subgroup analysis due to a relatively small number 
of patients and a lower event rate, the benefit of dapagliflozin on the primary endpoint 
seemed to be consistent with the effect in type 2 diabetes patients overall. 
 
Metformin was the most commonly used GLT in DAPA-HF, taken by approximately half of 
patients with type 2 diabetes and HFrEF, despite limited evidence for its cardiovascular 
safety in this patient group.
11
 Nevertheless, international HFrEF management guidelines 
support the use of metformin as first-line GLT in patients with type 2 diabetes.
12
 It has been 
suggested that the benefit of SLGT2i is contingent on metformin use, based upon a subgroup 
analysis of the CANVAS trials.
13
 This is clearly not the case from the present analysis of 
DAPA-HF or a post-hoc analysis of the EMPA-REG OUTCOME trial. 
14
 
 
Examination of outcomes in patients receiving the other major classes of GLT was also of 
interest. After metformin, insulin was the most widely used GLT and dapagliflozin was as 
effective in these participants, as compared to patients not taking insulin. Given the 
substantially higher event rate experienced by patients receiving insulin, compared to those 
 8 
receiving other GLT,
 
the relative risk reduction in insulin-treated individuals translated into 
an even larger absolute risk reduction and an NNT of only 16 to prevent one patient having 
the primary outcome over the median 18.2 months of follow-up.
 
 Furthermore, the benefits of 
dapagliflozin were again consistent whether added to a sulfonylurea or a DDP-4 inhibitor. 
 
We believe our findings are relevant to the discussion that followed recent updated guidance 
on management of diabetes issued by the European Society of Cardiology (ESC) and jointly 
by the American Diabetes Association (ADA) and European Association for the Study of 
Diabetes (EASD).
4-7
 Both recommendations emphasised that the cardiovascular benefits of 
SGLT2i, and GLP-1 receptor agonists, are obtained independently of starting HbA1c, an 
approach supported by the strategy employed in DAPA-HF. More controversially, the ESC 
guidance supported the use of SGLT2i, and GLP-1 receptor agonists, as “first-line” GLT and 
not necessarily as an adjunct to metformin, which had previously been the recommended 
initial GLT in most patients with cardiovascular disease.
7
 Our data also support this 
recommendation, at least in patients with HFrEF and provide further evidence, along with the 
evidence of benefit in HFrEF patients without diabetes, to the view that the mechanisms of 
action underlying the cardiovascular benefits of dapagliflozin are independent of any 
glucose-lowering effect.
15
 
 
As with all studies of this nature there are inherent limitations. The analyses were not 
prespecified and some had limited power, despite only including subgroups with >200 
individuals. The small number of patients taking a GLP-1 receptor agonist at baseline 
prohibited further examination of this subgroup. 
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Conclusion 
In patients with type 2 diabetes and HFrEF, the reductions in risk of worsening HF and 
cardiovascular death with dapagliflozin were consistent across a range of background of 
GLT, and in patients receiving no GLT. Our data provide support for the use of dapagliflozin 
as first-line monotherapy in type 2 diabetes, at least in patients with HFrEF. 
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FIGURE LEGENDS 
 
Figure 1: Effect of dapagliflozin compared to placebo on the risk of the primary 
composite outcome by background glucose-lowering therapy in patients with diabetes 
 
 
*Overall effect calculated in all randomized patients (n=4744) 
 
The primary outcome was a composite of worsening heart failure (hospitalization or an 
urgent visit resulting in intravenous therapy for heart failure) or death from cardiovascular 
causes. Patients on multiple glucose-lowering medications are included in each individual 
medication subgroup. 
 
DPP-4 = dipeptidyl peptidase-4; 12 patients were prescribed saxagliptin. 
CI = confidence interval. 
 
 
